Details of the Drug

General Information of Drug (ID: DM1O3BY)

Drug Name
Mecasermin
Synonyms Increlex (TN)
Indication
Disease Entry ICD 11 Status REF
Growth failure LD2F.1Y Approved [1]
Laron syndrome N.A. Investigative [2]
Therapeutic Class
Immunomodulatory Agents
Affected Organisms
Humans and other mammals
ATC Code
H01AC03: Mecasermin
H01AC: Somatropin and somatropin agonists
H01A: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
H01: PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
Sequence
GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMY
CAPLKPAKSA
ADMET Property
Bioavailability
The bioavailability of drug is 100% [3]
Clearance
The clearance of drug is 0.04 L/h/kg []
Half-life
The concentration or amount of drug in body reduced by one-half in 5.8 hours []
Metabolism
The drug is metabolized via the liver and kidney [4]
Vd
The volume of distribution (Vd) of drug is 0.257 +/- 0.073 L/kg []
Cross-matching ID
UNII
7GR9I2683O
DrugBank ID
DB01277
TTD ID
D0F3JT
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin-like growth factor I receptor (IGF1R) TTHRID2 IGF1R_HUMAN Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Growth failure
ICD Disease Classification LD2F.1Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Insulin-like growth factor I receptor (IGF1R) DTT IGF1R 1.64E-01 0.25 0.64
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mecasermin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Mecasermin and Insulin-glulisine. Acute diabete complication [5A2Y] [6]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Mecasermin and Insulin-aspart. Acute diabete complication [5A2Y] [7]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Mecasermin and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [6]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Mecasermin and Insulin degludec. Type-1/2 diabete [5A10-5A11] [6]

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 Cardiac examination in children with Laron syndrome undergoing mecasermin therapy. J Pediatr Endocrinol Metab. 2018 Jun 27;31(6):675-679.
3 Griffith RS: The pharmacology of cephalexin. Postgrad Med J. 1983;59 Suppl 5:16-27.
4 Kabasakalian P, Taggart M, Townley E: Urinary excretion of pheniramine and its N-demthylated metabolites in man--comparison with chlorpheniramine and brompheniramine data. J Pharm Sci. 1968 Apr;57(4):621-3. doi: 10.1002/jps.2600570416.
5 IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.
6 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
7 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]